首页> 美国卫生研究院文献>Diabetes Care >Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

【2h】

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

机译：单独使用人胰高血糖素样肽-1类似物他普鲁肽与二甲双胍联合治疗可改善单独控制二甲双胍的2型糖尿病患者的血糖控制并降低体重

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

OBJECTIVETo evaluate the efficacy and safety of taspoglutide (R1583/BIM51077), a human once-weekly glucagon-like peptide-1 analog, in patients with type 2 diabetes inadequately controlled with metformin.

机译：目的评估每周一次的人胰高血糖素样肽-1类似物他斯普鲁肽（R1583 / BIM51077）在二甲双胍控制不足的2型糖尿病患者中的疗效和安全性。

著录项

期刊名称 Diabetes Care
作者
Michael A. Nauck; Robert E. Ratner; Christoph Kapitza; Rachele Berria; Mark Boldrin; Raffaella Balena;
展开▼
作者单位

展开▼
年(卷),期 2009(32),7
年度 2009
页码 1237–1243
总页数 7
原文格式 PDF
正文语种
中图分类护理学;
关键词

相似文献

外文文献
中文文献
专利

1. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. [J] . Nauck MA, Ratner RE, Kapitza C Diabetes care . 2009,第7期

机译：每周一次的人胰高血糖素样肽-1类似物taspoglutide与二甲双胍联合治疗可改善血糖控制，并降低仅用二甲双胍无法控制的2型糖尿病患者的体重：一项双盲安慰剂对照研究。
2. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. [J] . Vilsboll T, Zdravkovic M, Le-Thi T, Diabetes care . 2007,第6期

机译：利拉鲁肽（一种长效人类胰高血糖素样肽1类似物）通过单一疗法显着改善了2型糖尿病患者的血糖控制并降低了体重，而没有低血糖的风险。
3. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy [J] . Judith L White, Patricia Buchanan, Jia Li, BMC Endocrine Disorders . 2014,第1期

机译：每日两次沙格列汀联合二甲双胍联合治疗2型糖尿病患者血糖控制不佳的疗效和安全性的随机对照试验
4. Controlled Release of Metformin Loaded Polyvinyl Alcohol (PVA) Microbubble/Nanoparticles Using Microfluidic Device for the Treatment of Type 2 Diabetes Mellitus [C] . Sumeyye Cesur, Muhammet Emin Cam, Fatih Serdar Sayin, International work-conference on bioinformatics and biomedical engineering . 2020

机译：使用微流体装置控制二甲双胍负载的聚乙烯醇（PVA）微泡/纳米颗粒的控释，用于治疗2型糖尿病
5. The relationship between the emotional burden of Type 2 Diabetes and glycemic control and differences in emotional burden and glycemic control among individuals treated with oral antidiabetic agents, combination therapy, incretin mimetic, and insulin [D] . Douaihy, Katharine 2008

机译：2型糖尿病患者的情绪负担与血糖控制之间的关系以及口服抗糖尿病药，联合疗法，降钙素模拟物和胰岛素治疗的个体之间情绪负担和血糖控制的差异
6. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy [O] . Judith L White, Patricia Buchanan, Jia Li, 2014

机译：每日两次沙格列汀联合二甲双胍联合治疗2型糖尿病患者的疗效和安全性以及二甲双胍单药的血糖控制不足的随机对照试验
7. Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study [O] . Nauck, Michael A., Ratner, Robert E., Kapitza, Christoph, 2009

机译：人单次胰高血糖素样肽-1类似物他普鲁肽与二甲双胍联合治疗可改善单独控制二甲双胍的2型糖尿病患者的血糖控制并降低体重：一项双盲安慰剂对照研究

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

摘要

著录项

相似文献

相关主题

期刊订阅